3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
51
Neoplasms
34
Colorectal Neoplasms
23
Lung Neoplasms
17
Prostatic Neoplasms
16
Melanoma
15
Neoplastic Cells, Circulating
13
Pancreatic Neoplasms
11
Multiple Myeloma
11
Uterine Cervical Neoplasms
10
Ovarian Neoplasms
10
Carcinoma, Non-Small-Cell Lung
8
Papillomavirus Infections
7
Neoplasm Metastasis
7
Leukemia, Myeloid, Acute
7
Colonic Neoplasms
7
Lymphoma, Follicular
6
Lymphoma
6
Hematologic Neoplasms
6
Uveal Melanoma
5
Sarcoma
5
Head and Neck Neoplasms
5
Glioma
5
Uterine Cervical Dysplasia
4
Urinary Bladder Neoplasms
4
Rectal Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Glioblastoma
4
Disease
4
COVID-19
4
Interventions
Bortezomib
5
Dexamethasone
4
Lenalidomide
3
Granulocyte Colony-Stimulating Factor
3
fludarabine
2
filanesib
2
dacetuzumab
2
Steroids
2
Injections, Subcutaneous
2
Filgrastim
2
plerixafor
1
ofatumumab
1
isatuximab
1
fludarabine phosphate
1
ficlatuzumab
1
birtamimab
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Vorinostat
1
Tacrolimus
1
Rifaximin
1
Proteasome Inhibitors
1
Plasma Exchange
1
Mycophenolic Acid
1
KW-2478
1
Hsp90 inhibitor KU757
1
Erlotinib Hydrochloride
1
Denosumab
1
Cyclophosphamide
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Paraproteinemias
×
Blood Specimen Collection
×
Clear all
NCT01543100
2014-01-06
PACMoG
Rennes University Hospital
Phase NA
Completed
60 enrolled